{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:54:43Z","timestamp":1789343683117,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81603467"],"award-info":[{"award-number":["81603467"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Key Specialty of Traditional Chinese Clinical Medicine","award":["shslczdzk01201"],"award-info":[{"award-number":["shslczdzk01201"]}]},{"name":"\u201cTree-Year Action Plan\u201d for Development of TCM in Shanghai","award":["16CR1026B"],"award-info":[{"award-number":["16CR1026B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Portal vein thrombosis (PVT) is a common complication of liver cirrhosis that can aggravate portal hypertension. However, there are features of both PVT and cirrhosis that are not recapitulated in most current animal models. In this study, we aimed to establish a stable animal model of PVT and cirrhosis, intervene with anticoagulant, and explore the related mechanism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>First, 49 male SD rats received partial portal vein ligation (PPVL), and 44 survival rats were divided into 6 groups: PPVL control group; 4-week, 6 -week, 8-week, and 10-week model group; and the rivaroxaban (RIVA)-treated group. The rats were intoxicated with or without carbon tetrachloride (CCl<jats:sub>4<\/jats:sub>) for 4\u201310 weeks. Seven normal rats were used as the normal controls. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and parameters for blood coagulation were all assayed with kits. Liver inflammation, collagen deposition and hydroxyproline (Hyp) levels were also measured. The extrahepatic macro-PVT was observed via portal vein HE staining, etc. The intrahepatic microthrombi was stained via fibrin immunohistochemistry. The portal blood flow velocity (PBFV) and diameter were detected via color Doppler ultrasound. Vascular endothelial injury was evaluated by von Willebrand Factor (vWF) immunofluorescence. Fibrinolytic activity was estimated by western blot analysis of fibrin and plasminogen activator inhibitor-1 (PAI-1).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After PPVL surgery and 10 weeks of CCl<jats:sub>4<\/jats:sub> intoxication, a rat model that exhibited characteristics of both cirrhosis and extra and intrahepatic thrombi was established. In cirrhotic rats with PVT, the PBFV decreased, both factors of pro- and anti-coagulation decreased, but with relative hypercoagulable state, vascular endothelial injured, and fibrinolytic activity decreased. RIVA-treated rats had improved coagulation function, increased PBFV and attenuated thrombi. This effect was related to the improvements in endothelial injury and fibrinolytic activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A new rat model of PVT with cirrhosis was established through partial portal vein ligation plus CCl<jats:sub>4<\/jats:sub> intoxication, with the characteristics of macrothrombi at portal veins and microthrombi in hepatic sinusoids, as well as liver cirrhosis. Rivaroxaban could attenuate PVT in cirrhosis in the model rats. The underlying mechanisms of PVT formation in the rat model and pharmacological action of rivaroxaban are related to the regulation of portal blood flow, coagulant factors, and vascular endothelial cell function.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03253-4","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T14:03:19Z","timestamp":1715608999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban"],"prefix":"10.1186","volume":"24","author":[{"given":"Yanan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"issue":"2","key":"3253_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","volume":"75","author":"M Senzolo","year":"2021","unstructured":"Senzolo M, Garcia-Tsao G, Garc\u00eda-Pag\u00e1n JC. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol. 2021;75(2):442\u201353.","journal-title":"J Hepatol"},{"issue":"27","key":"3253_CR2","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4254\/wjh.v7.i27.2774","volume":"7","author":"JG Stine","year":"2015","unstructured":"Stine JG, Shah PM, Cornella SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis[J]. World J Hepatol. 2015;7(27):2774\u201380.","journal-title":"World J Hepatol"},{"issue":"6","key":"3253_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.clinre.2015.02.012","volume":"39","author":"X Qi","year":"2015","unstructured":"Qi X, Su C, Ren W, et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: a systematic review of the literature[J]. Clin Res Hepatol Gastroenterol. 2015;39(6):683\u201391.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"3253_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease[J]. N Engl J Med. 2011;365(2):147\u201356.","journal-title":"N Engl J Med"},{"issue":"31","key":"3253_CR5","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.3748\/wjg.v25.i31.4437","volume":"25","author":"M Faccia","year":"2019","unstructured":"Faccia M, Ainora ME, Ponziani FR, et al. Portal vein thrombosis in cirrhosis: why a well-known complication is still matter of debate[J]. World J Gastroenterol. 2019;25(31):4437\u201351.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3253_CR6","first-page":"154","volume":"7","author":"M Wu","year":"2019","unstructured":"Wu M, Schuster M, Tadros M. Update on management of portal vein thrombosis and the role of novel anticoagulants[J]. J Clin Transl Hepatol. 2019;7(2):154\u201364.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"3253_CR7","first-page":"29","volume":"40","author":"Z Liu","year":"2024","unstructured":"Liu Z, Chen JH, Qi XS, et al. Establishment and application of animal models for portal vein thrombosis[J]. J Clin Hepatol. 2024;40(1):29\u201332.","journal-title":"J Clin Hepatol"},{"issue":"13","key":"3253_CR8","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1182\/blood.V96.13.4222","volume":"96","author":"J Cui","year":"2000","unstructured":"Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation[J]. Blood. 2000;96(13):4222\u20136.","journal-title":"Blood"},{"issue":"6","key":"3253_CR9","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/hep.29084","volume":"65","author":"M Vilaseca","year":"2017","unstructured":"Vilaseca M, Garc\u00eda-Calder\u00f3 H, Lafoz E, et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells[J]. Hepatology. 2017;65(6):2031\u201344.","journal-title":"Hepatology"},{"issue":"27","key":"3253_CR10","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.11569\/wcjd.v21.i27.2765","volume":"21","author":"W Huang","year":"2013","unstructured":"Huang W, Qian JR. Treatment with valsartan reduces TGF-\u03b21 expression and collagen fiber content in the portal vein of rats with portal hypertensive gastropathy[J]. WJG. 2013;21(27):2765\u201371.","journal-title":"WJG"},{"key":"3253_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4939-7113-8_7","volume":"1627","author":"S Klein","year":"2017","unstructured":"Klein S, Schierwagen R, Uschner FE, et al. Mouse and rat models of induction of hepatic fibrosis and Assessment of Portal Hypertension[J]. Methods Mol Biol. 2017;1627:91\u2013116.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"3253_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0003-2697(81)90261-X","volume":"112","author":"IS Jamall","year":"1981","unstructured":"Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues[J]. Anal Biochem. 1981;112(1):70\u20135.","journal-title":"Anal Biochem"},{"issue":"36","key":"3253_CR13","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.3748\/wjg.v18.i36.5014","volume":"18","author":"FR Ponziani","year":"2012","unstructured":"Ponziani FR, Zocco MA, Garcovich M, et al. What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective[J]. World J Gastroenterol. 2012;18(36):5014\u201320.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3253_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/1751-2980.12970","volume":"22","author":"Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association","year":"2021","unstructured":"Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai) [J]. J Dig Dis. 2021;22(4):176\u201386.","journal-title":"J Dig Dis"},{"issue":"1","key":"3253_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hep.31646","volume":"73","author":"PG Northup","year":"2021","unstructured":"Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular Liver disorders, portal vein thrombosis, and procedural bleeding in patients with Liver Disease: 2020 Practice Guidance by the American Association for the study of Liver Diseases[J]. Hepatology. 2021;73(1):366\u2013413.","journal-title":"Hepatology"},{"issue":"4","key":"3253_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/hep.32169","volume":"75","author":"EG Driever","year":"2022","unstructured":"Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus[J]. Hepatology. 2022;75(4):898\u2013911.","journal-title":"Hepatology"},{"issue":"2","key":"3253_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/rth2.12191","volume":"3","author":"M Pieters","year":"2019","unstructured":"Pieters M, Wolberg AS. Fibrinogen and fibrin: an illustrated review[J]. Res Pract Thromb Haemost. 2019;3(2):161\u201372.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"3253_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","volume":"51","author":"MA Zocco","year":"2009","unstructured":"Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol. 2009;51(4):682\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"3253_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/liv.13500","volume":"38","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wang J, Shah PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: a matched case-control study[J]. Liver Int. 2018;38(1):94\u2013101.","journal-title":"Liver Int"},{"issue":"2","key":"3253_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2010.01.042","volume":"53","author":"T Lisman","year":"2010","unstructured":"Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs[J]. J Hepatol. 2010;53(2):362\u201371.","journal-title":"J Hepatol"},{"issue":"5","key":"3253_CR21","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.7861\/clinmed.2020-0346","volume":"20","author":"EE Ladikou","year":"2020","unstructured":"Ladikou EE, Sivaloganathan H, Milne KM, et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?[J] Clin Med (Lond). 2020;20(5):e178\u201382.","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"3253_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1055\/s-0042-1758791","volume":"49","author":"GB Morrow","year":"2023","unstructured":"Morrow GB, Mutch NJ. Past, Present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1) [J]. Semin Thromb Hemost. 2023;49(3):305\u201313.","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"3253_CR23","doi-asserted-by":"publisher","first-page":"11721","DOI":"10.1074\/jbc.M207728200","volume":"278","author":"C Liu","year":"2003","unstructured":"Liu C, Ga\u00e7a MD, Swenson ES, et al. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of smads in activated cells is TGF-beta-independent[J]. J Biol Chem. 2003;278(13):11721\u20138.","journal-title":"J Biol Chem"},{"issue":"7","key":"3253_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol. 2017;14(7):397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03253-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T14:05:33Z","timestamp":1715609133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03253-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03253-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the institutional animal ethics committees of the Laboratory Animal Center at Shanghai University of Traditional Chinese Medicine, Shanghai, China (Ethics Number: SZY201804011). All protocols and experimental procedures were conducted in accordance with the relevant institutional guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}